Product

Zenocutuzumab

Aliases

bispecific, MCLA-128, zenocutuzumab (MCLA-128)

Name

Zenocutuzumab

2 clinical trials

1 drug

5 indications

8 posters

Indication

Breast Cancer Metastatic

Indication

Solid Tumors Harboring NRG1 Fusion

Indication

NSCLC Harboring NRG1 Fusion

Indication

Pancreatic Cancer

Indication

Drug

Clinical trial

Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

Status: Completed, Estimated PCD: 2022-10-26

Clinical trial

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)

Status: Recruiting, Estimated PCD: 2026-12-31

Poster

The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions

Poster

The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions

Poster

The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions

Poster

ANTI-TUMOR ACTIVITY IN NRG1+ PDAC

Poster

Durable efficacy of zenocutuzumab, a HER2 × HER3 bispecific antibody, in advanced NRG1 fusion–positive (NRG1+) non-small cell lung cancer (NSCLC)

Poster

Zenocutuzumab, an antibody that can overcome HER3 mediated NRG1 signaling in tumor cells by docking on HER2

Poster

Phase 2 study of Zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors

Poster

Zenocutuzumab, a HER2 × HER3 bispecific antibody, is effective in cancer models with high NRG1 expression